Drug targeting is an active area of research and nano-scaled drug delivery systems hold tremendous potential for the treatment of neoplasms. In this study, a novel cyclodextrin (CD)-based nanoparticle drug delivery system has been assembled and characterized for the therapy of folate receptor-positive [FR(+)] cancer. Water-soluble folic acid (FA)-conjugated CD carriers (FACDs) were successfully synthesized and their structures were confirmed by 1D/2D nuclear magnetic resonance (NMR), matrix-assisted laser desorption ionization time-of-flight mass spectrometer (MALDI-TOF-MS), high performance liquid chromatography (HPLC), Fourier transform infrared spectroscopy (FTIR), and circular dichroism. Drug complexes of adamatane (Ada) and cytotoxic doxorubicin (Dox) with FACD were readily obtained by mixed solvent precipitation. The average size of FACD-Ada-Dox was 1.5-2.5 nm. The host-guest association constant K a was 1,639 M 21 as determined by induced circular dichroism and the hydrophilicity of the FACDs was greatly enhanced compared to unmodified CD. Cellular uptake and FR binding competitive experiments demonstrated an efficient and preferentially targeted delivery of Dox into FR-positive tumor cells and a sustained drug release profile was seen in vitro. The delivery of Dox into FR(+) cancer cells via endocytosis was observed by confocal microscopy and drug uptake of the targeted nanoparticles was 8-fold greater than that of non-targeted drug complexes. Our docking results suggest that FA, FACD and FACD-Ada-Dox could bind human hedgehog interacting protein that contains a FR domain. Mouse cardiomyocytes as well as fibroblast treated with FACD-Ada-Dox had significantly lower levels of reactive oxygen species, with increased content of glutathione and glutathione peroxidase activity, indicating a reduced potential for Dox-induced cardiotoxicity. These results indicate that the targeted drug complex possesses high drug association and sustained drug release properties with good biocompatibility and physiological stability. The novel FA-conjugated b-CD based drug complex might be promising as an anti-tumor treatment for FR(+) cancer.
Introduction
Cancer is a leading killer of human beings worldwide, accounting for 7.6 million deaths (around 13% of all deaths) in 2008 [1] . Overall, an estimated 12.7 million new cancer cases and 7.6 million cancer deaths occurred in 2008, with 56% of new cancer cases and 63% of the cancer deaths occurring in the less developed regions of the world [2] . The most commonly diagnosed cancers worldwide are lung (1.61 million, 12.7% of the total), breast (1.38 million, 10.9%) and colorectal cancers (1.23 million, 9.7%). Novel, safe and effective treatments are clearly and urgently needed to curtail these high mortality statistics. The four major modules of cancer treatment include surgery, radiation, chemotherapy and immunotherapy [3] . However, these therapies are only successful when the cancer is detected at an early stage, or limited to certain types of cancer (e.g., leukemia). Due to the inability of detecting cancer at an early stage, most patients present in the advanced stage with extensive local infiltration and metastasis. For advanced tumors, in particular those tumors developed from epithelial tissues such as lung, colon, breast, prostate and pancreas, these therapies are less successful. Chemotherapy represents one of the major means for cancer treatment, which aims to kill tumor cells or to inhibit their proliferation while preserving the normal cells in the body [3] . Chemotherapeutic agents generally have a narrow margin of safety, and are used in combination usually given at a maximum tolerated dose to achieve maximum cancer cell killing [4] . They kill tumor cells by direct cytotoxicity, or activating host immune response, inhibiting the proliferation processes of tumor cells, and inducing apoptosis [5] . However, most patients do not respond to these drugs and they often experience severe adverse effects such as severe diarrhea and loss of hairs. The primary reason for this is because the drug kills both normal and tumor cells due to low drug selectivity and drug levels within tumor cells are too low. Drug resistance and dose-limiting toxicities are the major problems for the success of cancer chemotherapy [6] . In the past decade, nanoscaled, targeted drug delivery has attracted much attention as a means to improve the curative effect of existing chemotherapeutic agents while reducing their adverse effects [7, 8] . Recent dramatic developments in nanotechnology have created a myriad of anticancer nano-drugs; however, most current nano-drug systems fall short in ease of purification, reproducibility and batch-to-batch consistency [9, 10] . The preparation and characterization of nanodrug formulations especially for aqueous drug complexes remains a major challenge.
The anthracycline glycoside antibiotic, doxorubicin (Dox), is a potent, broad-spectrum anticancer agent that acts by intercalating within DNA and inhibiting DNA synthesis [11] . Dox is often used to treat some leukemias and Hodgkin's lymphoma, as well as cancers of the bladder, breast, stomach, lung, ovaries, thyroid, and soft tissue sarcoma. At the usual chemotherapeutic doses, Dox is cardiotoxic and it may also increase the risk of leukemia especially when it is given at high doses or together with certain other chemotherapeutic agents or radiation therapy [11] [12] [13] [14] [15] [16] .
The aim of this report is to present a method for synthesizing a novel and effective drug complex for targeted drug delivery ( Figure 1) . Combining targeting molecules, drug carriers and cytotoxic agents into a complex should guarantee the stability of the conjugate in circulation and insure cleavability to release the drug. The b-CD was vectorized with folic acid (FA) to target folate receptors (FRs) on the tumor cell surface. Dox-containing FRtargeting b-CDs were synthesized by a multi-step reaction in which a-and c-amide monomers as well as the di-CD substituted FA carrier were purified and fully characterized by a panel of spectral techniques. The in vitro drug release profile was determined by dialysis and fluorescence measurement, and targeted drug binding in vitro was quantitated by flow cytometry and confocal microscopy. The cytotoxicity of the different drug complexes was measured and the biomarkers related to free Doxinduced cardiotoxicity were also examined at the cellular level.
Materials and Methods

Chemicals and Reagents
b-Cyclodextrin hydrate and cerim (IV) sulphate tetrahydrate were purchased from Acros Organics (Thermo Fisher Scientific, Waltham, MA). Ammonium molybdate (para) tetrahydrate was purchased from Alfa Aesar Inc. (Ward Hill, MA). p-Toluenesulfonyl chloride, N, N'-dicyclohexyl-carbodiimide (DCC), folic acid (FA), Nhydroxysuccinimide (NHS), doxorubicin hydrochloride, 1-adamantanecarbonyl chloride, ammonium bicarbonate, sodium azide, triphenylphosphine, 29, 79-dichlorofluorescein diacetate (DCFH-DA), 5, 59-dithiobis(2-nitrobenzoic acid) (DTNB), reduced glutathione (GSH), hydrogen peroxide, potassium hydroxide, sodium hydroxide, phosphoric acid, ammonia hydroxide, ninhydrin, hydrochloric acid, iodine, sulfuric acid, acetic acid, deuterium oxide, chloroform-d, dimethyl sulfoxide-d 6 , and CM sephadex C 25 were all purchased from Sigma-Aldrich Chemicals Co. (St. Louis, MO). Paraformaldehyde was obtained from EMD Chemicals Inc. (Gibbstown, NJ). The bicinchoninic acid (BCA) assay kit was purchased from Pierce (Rockford, IL). CM-H 2 DCFDA was purchased from Invitrogen (Carlsbad, CA). The Pro-prep (TM) Protein extraction kit was purchased from iNtRon Biotechnology Inc. (Kyungki-Do, Korea). The glutathione peroxidase (GPx) assay kit was obtained from BioVision Inc. (Milpitas, CA). Spectra/Por dialysis membrane with a molecular weight cutoff of 3,000 Da was purchased from Spectrum Laboratories (Rancho Dominguez, CA). All solvents for chromatographic isolation were of analytical grade. HPLC-grade acetone, butanol, acetonitrile (ACN), ethyl acetate (EtOAc), hexane, methanol, 1-propanol (1-PA), 2-propanol, dichloromethane (DCM), pyridine, dimethylformamide (DMF), dimethyl sulfoxide (DMSO) and thin layer chromatography plates (1,000 mm and 200 mm) were purchased from Fisher Scientific Co. (Fair lawn, NJ). Heat-inactivated fetal bovine serum, fetal bovine serum, and newborn calf serum were purchased from Hyclone Laboratories Inc. (Logan, UT). FR and b-actin antibody were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). HRP mouse anti-rabbit IgG monoclonal antibody was purchased from ProSci Inc. (San Diego, CA). Pierce ECL western blotting substrate was purchased from Thermo Fisher Scientific Inc. (Waltham, MA).
Cells and Cell Culture
JEG-3 and JAR (both derived from human placenta choriocarcinoma), HT-29 (human colon cancer), MCF-7 (human breast cancer), H9C2(2-1) cells (mouse cardiomyocytes) and 3T3 (mouse fibroblast) cell lines were purchased from American Type Culture Collection (ATCC, Rockville, MD). JEG-3 cells were cultured in Dulbecco's modified Eagle medium (DMEM) with 10% newborn calf serum; JAR and MCF-7 cells were cultured in RPMI-1640 with 10% newborn calf serum; HT-29 cells were cultured in McCoy's 5A with 10% newborn calf serum; and 3T3 cells were cultured in DMEM with 10% fetal calf serum. All cell lines were incubated in 5% CO 2 and 90-100% relative humidity at 37uC. Medium renewal was carried out 2-3 times per week, and cells were subcultured when they achieved 80-90% confluence. For slide preparation, 2610 4 cells were plated on 0.7 cm60.7 cm Nunc brand chamber slides from Thermo Fisher Scientific (Waltham, MA). Cells were washed three times in phosphate-buffered saline (PBS) and overlayed with Vectashield brand mounting medium containing 4,6-diamidino-2-phenylindole (DAPI) purchased from Vector Laboratories Inc. (Burlingame, CA).
Western Blot Assay
The protein content was determined using the BCA method after protein extraction from the cells. The expression level of FR in JAR, HT-29, MCF-7 and 3T3 cell lines was determined by Western blot assay. Briefly, cell monolayers were washed with PBS and then the lysates were boiled for 10 min and an aliquot was used to evaluate the protein content by BCA assay. An aliquot of total protein (0.2 mg) was analyzed by 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). After electroblotting of gels onto polyvinylidene difluoride (PVDF) sheets (Millipore, Bedford, MA), the filters were blocked at room temperature with the Tris-buffered saline Tween-20 (TBST) buffer (10 mM Tris-HCl, pH 8.0, 0.1% Tween 20, and 150 mM NaCl) containing 10% non-fat dry milk and then incubated in TBST buffer overnight at 4uC with a 1:200 dilution of FR antibody and 1:10,000 dilution for b-actin antibody. After washing with TBST buffer, blots were incubated for 1 hr at room temperature with mouse anti-rabbit IgG monoclonal antibody diluted 1:3,000 in TBST buffer and then revealed by enhanced chemiluminescence (ECL).
Chemical Synthesis of Folic Acid Receptor-Targeted, b-
Cyclodextrin-Based Drug Complexes
To synthesize mono-6-deoxy-6-(p-tolylsulfonyl)-b-cyclodextrin (Ts-CD), a solution of p-toluenesulfonyl chloride (846.3 mg, 4.44 mmol) in 5 ml ACN was added to 80 ml aqueous solution of b-CD (5.0 g, 4.44 mmol) and NaOH (434.8 mg, 10.8 mmol) dropwise over 15 min. After stirring for 4 hr at 0uC in N 2 atmosphere, the solution was neutralized by adding 0.6 ml of 2.0 N aqueous hydrochloric acid and the product was recrystallized at 4uC overnight, and then washed with acetone. Ts-CD was obtained in a yield of 84.6% ( Figure 2 and Figures S1 & S2) .
Mono-6-azido-6-deoxy-b-cyclodextrin (N 3 -CD) was obtained by the reaction of Ts-CD and sodium azide for 5 hr at 80uC with a yield of 91.5%. Mono-6-deoxy-6-aminob-cyclodextrin (NH 2 -CD): N 3 -CD and triphenyl phophine were dissolved in DMF, and ammonia solution was added and the solution stirred for 3 days at 50uC. The final solution was recrystallized in acetone to give the compound NH 2 -CD in 79% yield ( Figure 2 and Figure S3 ), which was purified by ion exchange column with deionized water and 0.1 M (NH 4 ) 2 CO 3 .
Ada-COCl was dissolved in anhydrate DCM mixed with Et 3 N, and then stirred at room temperature for 3 hr under N 2 . Doxorubicin hydrochloride was then added, stirred overnight and separated by preparative thin layer chromatography (TLC). Ada-Dox was obtained and purified by flash column with a yield of 80.5% ( Figure 2 and Figure S4) .
A mixture of folic acid (20 mg, 0.045 mmol), 1.2 equivalents of DCC (11 mg, 0.054 mmol) and 1.2 equivalents NHS (6 mg, 0.054 mmol) in anhydrous DMF (5 ml) was stirred at room temperature under a nitrogen atmosphere and in a dark for 3 hr. Thereafter, 50 mg of NH 2 -CD (1 equivalent) and 0.8 ml pyridine were added and the mixture was stirred at room temperature in the dark for 8-40 hr. The reaction mixture was then precipitated with 50 ml of acetone and rinsed sequentially three times with 50 ml of acetonitrile, ethyl acetate, and ethanol to remove hydrophobic side products. The resulting yellow precipitate (48 mg) was collected by centrifugation and dissolved in 20 ml deionized water. A clear aqueous solution (15 ml) was obtained by vacuum filtration, which was dialyzed extensively against deionized water for one week, with dialysis water being renewed every day. The aqueous solution was concentrated down to 5 ml and was chromatographed on a CM sephadex C 25 ion exchange flash column with deionized water and followed by preparative thin liquid chromatography eluted with 1-PA: EtOAc: H 2 O: NH 3 H 2 O (6:1:2.5:1). The products contained the folic acid conjugates and another oily yellow byproduct with polarity similar to the desired product. Finally, the diastereomers were totally purified by recrystallization in acetone three times, and dried in a vaccum oven overnight. This resulted in the products, mono-6-deoxy-6-(c- The formation of guest-host inclusion complexes between AdaDox and folic acid-conjugated cyclodextrins was prepared by coprecipitation and drying method with 1:1 stoichiometry. FACDs (1 eq) were dissolved in water, and the DMSO solution of AdaDox (1 eq) was added to the cyclodextrin solution and then stirred overnight at 4uC followed by partial evaporation. The precipitate was collected by filtration. 
High Performance Liquid Chromatography (HPLC)
HPLC analyses were carried out on an Agilent 1260 Infinity HPLC system (Agilent Technologies Inc., Santa Clara, CA) that included G1312C solvent delivery binary pumps, a G1379B degasser, a G1329B auto-sampler, a G4212B photo-diode array detector, a G1321B Fluorescence detector, and the Chemstation operating software (Rev. B. 04. 03). The HPLC was equipped with an Agilent Eclipse Plus C 18 column with a particle size of 3.5 mm and column size of 100 mm64.6 mm, which was placed in a column oven (G1316A) under a constant temperature at 25uC. The mobile phase consisted of acetonitrile and water (Gradient). The column flow rate was set at 1.0 ml/min, while the HPLC pressure was controlled between 260-290 bars.
The HPLC-UV/evaporative light scattering detector (ELSD) and the HPLC-DAD/fluorescence separation conditions were as follows: eluent A, water; eluent B, acetonitrile; gradient, 0-6 min (10-15% B), 6-50 min (15-40% B), 50-60 min (40-80% B), and then equilibrated with 10% B for 8 min at a flow of 1.0 ml/min. ELSD was set at a probe temperature of 70uC, a gain of 7 and the nebulizer gas nitrogen adjusted to 2.5 bars.
Fourier Transform Infrared Spectroscopy (FTIR)
The instrument used for FTIR analysis was a Perkin-Elmer 1725 series FTIR spectrometer (Perkin-Elmer Co., Norwalk, CT) equipped with a room temperature deuterated triglycine sulfate detector and controlled by a Perkin-Elmer 7300 PC. The software used for collecting the FTIR data was the Spectrum version 5.3.1.
Circular Dichroism Analysis
Circular dichroism spectra were recorded at 25uC in an Aviv model 215 circular dichroism spectrometer (Aviv Biomedicals Inc., Lakewood, NJ) using a 0.1 cm cell for three scans with 0.1 nm bandwidth. The concentration of the drugs was 50 mM in DMF unless otherwise indicated. The Synergy H4 hybrid multi-mode microplate reader was purchased from BioTek Instruments Inc. (Winooski, VT).
Transmission Electron Microscopy (TEM) and Atomic Force Microscopy (AFM)
The morphology and size of the FACD-Ada-Dox supramolecules were evaluated by transmission electron microscopy (TEM) and atomic force microscopy (AFM). An aqueous solution of FACD-Ada-Dox was directly trickled onto a 300-mesh copper grid and dried in a vacuum oven at 35uC for 4 hr, then images were observed by TEM (JEM 100CX; JEOL Ltd, Tokyo, Japan) with an accelerating voltage of 160 kV. For AFM images, the sample was dissolved in double deionized water (1.0 mg/ml), an aliquot of the solution (5.0 ml) was spotted onto a freshly cleaved mica surface and heated at 37uC for 3 hr. Imaging was performed on a Multimode Nanoscope AFM in tapping mode, using a fluid cell, J scanner and 200 mm cantilevers with 1 nm Si 3 N 4 tips. Ada-Dox at different concentrations and incubated for 24 hr at 37uC. The absorbance was measured after adding MTT. MTT is reduced by mitochondrial dehydrogenases in living cells to a bluemageta coloured formazan precipitate. The absorbance of dissolved formazan in the visible region correlates with the number of intact active cells. The cytotoxicity was evaluated with reference to the IC 50 value that was defined as the concentration needed for a 50% reduction of survival based on the survival curves. IC 50 values were calculated from dose-response curves (i.e., cell survival fraction vs. drug concentration) obtained in multireplicated experiments.
Drug Release Assay
The in vitro release profiles and kinetics of the targeting drug FACD-Ada-Dox and prodrug Ada-Dox were determined by a dialysis method. Briefly, 3 ml of aqueous drug was added to 1 ml PBS (pH 7.4, 0.01 M). The mixture was suspended in a dialysis bag (molecular weight cutoff: 3,000 Dal) and dialyzed against 10 ml of PBS containing 50% fetal bovine serum (FBS) at 37uC with gentle shaking for three days. A 20 ml aliquot of the sample was withdrawn from the incubation medium at designated time points and stored frozen for analysis. The released Ada-Dox was quantified by microplate reader at l Ex = 490 nm and l Em = 600 nm. A calibration curve was prepared using different concentrations of free Ada-Dox.
Flow Cytometry
Flow cytometric analysis was performed on a FACS (Becton Dickinson Immunocytometry Systems, San Jose, CA) by counting 10,000 events. To evaluate the apoptosis of cells treated with various drugs at equivalent concentrations, Dox, Ada-Dox, FACD-Ada-Dox and NFACD-Ada-Dox at a final concentration of 5.0 mM were added into the prepared 35-mm petri dishes containing 2610 5 HT-29, MCF-7, or JAR cells in 3.0 ml culture medium. The cells were incubated for 2 hr to allow uptake of the drugs. Before analysis, the cells were carefully washed with PBS three times, trypsinized and resuspended in the medium after incubation. The collected cells were re-dispersed in 500 ml of fresh PBS and stained with 20 ml DAPI at 1.0 mM for flow cytometric analysis. The fluorescence of Dox-related molecule was measured with l EX at 490 nm and l EM at 600 nm. The untreated cells incubated with DMEM alone (containing 10% FBS, supplemented with 1% of penicillin) were used as the controls.
Folate Receptor-Binding Competition Assay
In the drug uptake competition assay, JAR cells (FR positive) were seeded into 35-mm petri dishes containing 5610 5 cells and incubated at 37 uC with FACD-Ada-DOX at 2 mM for 5 hr in the presence of FA at 5, 10 or 50 mM. Afterwards, the cells were washed with PBS three times, trypsinized and resuspended in the PBS. The collected cells were re-dispersed and the fluorescence intensities were determined by flow cytometer.
Confocal Laser Scanning Microscopy
Confocal images were recorded with a PerkinElmer ultraview ERS spinning disk confocal microscope (PerkinElmer Inc., Waltham, MA). JAR or JEG-3 cells were seeded on cover slips in two-well plates, and cultured overnight. Cells were then incubated with or without 5.0 mM drugs for 2 hr. The cells were washed with PBS three times to remove unbound drugs and fixed in 2 ml of 4% paraformade at room temperature for 15 min. Fixed cells were washed three times and then mounted with medium containing DAPI (1.5 mg/ml). Slides were cured overnight in the dark. To study the uptake of drugs over 2 hr in cells treated with different drug complexes, the cells were exposed to drugs with different incubation times (15 min increment). The images were collected and analyzed.
Molecular Docking of the Binding of FA and Its Conjugates to Human Hedgehog Interacting Protein (HHIP)
Unfortunately, the crystal structures of human and animal RCF/SLC19A1, FR/FRa/FLOR1, FRb/FLOR2, FRc/ FLOR3, FRd/FLOR4 and PCFT/SLC46A1 have not been resolved so far. No structures of bacterial and yeast homologs have been reported and thus it is unlikely to build up a homology model. We conducted preliminary docking study of FA and its conjugates to HIPP that contains a FRa domain was examined using the Discovery Studio 3.1 (Accelrys Software Inc., San Diego, CA) as described by us previously [17, 18] . Several functional Modules in Discovery Studio 2.1 were applied, including Diverse Conformation Generation, Calculate Molecular Properties, Create Multiple Linear Regression Model, and CDOCKER. The program was run using a Dell optiplex755 server and Chemoffice2002 (CambridgeSoft, Cambridge, MA) was used for compound structural refinement. The crystal structure of HHIP was selected from the Protein Data Bank (http://www.rcsb.org/pdb/) with the PDB ID of 2WFT [19] that was found to contain a FRa domain when we searched the Pcam 26.0 database (http://pfam. sanger.ac.uk/). The Pfam database is a large collection of protein families, each represented by multiple sequence alignments and hidden Markov models. The molecular dynamics (MD) simulated annealing process was performed using a rigid protein and flexible ligand. The ligand-FRa interactions were computed from either GRID I, GRID II, or the full force field. A final minimization step was applied to each of the ligand's docking poses. During ligand preparation, the duplicate structure was deleted. The options for ionization change, tautomer or isomer generation, Lipinski filter and 3D generator were all set true [20] . After refined with CHARMM, the compounds were docked into the possible binding site of the protein. The docking was carried out with consideration of electrostatic energy and van der Waals (vdW) force, which were softened at different levels during the docking process, but this softening is removed for the final minimization [21] .For each defined vdW or electrostatic probe, the interactions with all protein atoms were stored at these grid points. For ligand atoms located between grid points, a tri-linear interpolation was used to approximate the energies. A harmonic potential with the force constant of 300 kcal/mol was applied outside the grid boundary.
Determination of Cellular Reactive Oxygen Species (ROS) Levels
The intracellular ROS levels in mouse H9C2(2-1) cells were quantified using CM-H 2 DCFDA as the probe for ROS production [22] . CM-H 2 DCFDA is a chloromethyl derivative of H 2 DCFDA, useful as an indicator for ROS in cells. H9C2(2-1) cells were seeded on a dish at a density of 3610 6 cells per well and cultured in 5% CO 2 at 37uC for 24 hr. The cells were treated with Dox, Ada-Dox, FACD-Ada-Dox, or NFACD-Ada-Dox, and then rinsed with PBS. Afterward, the fluorescence intensity was measured. The drug concentration was 2.0 mM in H9C2(2-1) cells. The control cells were treated with the vehicle DMSO at a final concentration of 0.05% (v/v).
Intracellular ROS levels in mouse 3T3 cells were quantified using the dichlorofluorescein assay [23] . 3T3 cells were seeded on a 96-well plate at a density of 10 5 cells per well and cultured in 5% CO 2 at 37uC for 24 hr. The cells were treated with Dox, AdaDox, or FACD-Ada-Dox at 5.0 mM, then the cells were then rinsed by PBS, subsequently 75 ml of PBS, and 25 ml solution of 2',7'-dichlorfluorescein-diacetate (DFCH-DA) at a final concentration 62.5 mM in PBS buffer was added to each well. The fluorescence from each well was measured at 35uC immediately after incorporation of the reagent and every 5 min for 1 hr with 1 sec integration time, using 485 and 535 nm as excitation and emission wavelengths. Recording of the fluorescence intensity with time was used as an index of the individual intracellular levels of ROS in 3T3 cells. The response of the method was checked using a H 2 O 2 curve. Five independent experiments were performed per treatment.
Measurement of Glutathione Peroxidase (GPx) Activity and GSH Content
The protein content was determined using the BCA method after protein extraction from the cells. The activities of GPx and the content of GSH were scaled to protein content to correct for differences in biomass of the diverse homogenates. The levels of GSH in the cells were determined according to the method of Beutler et al. [24] based on the formation of 2-nitro-5-tiobenzoic acid from DTNB in the presence of GSH. In brief, 25 ml of trichloroacetic acid (15%) was added to 50 ml of the homogenate, followed by centrifugation at 13, 000 g for 5 min at 4uC. A supernatant aliquot (50 ml) was mixed with 50 ml of 3.4 mM ethylenediaminetetraacetic acid (EDTA) dissolved in PBS, 1 ml of PBS, and 250 ml of DTNB in PBS (20 mg/ml). The absorbance was measured at 412 nm after 15 min and compared to a standard curve of GSH (0.01-0.5 mM). The GPx activity was measured based on the oxidation of GSH by GPx coupled to the disappearance of reduced nicotinamide adenine dinucleotide phosphate (NADPH) by glutathione reductase.
Statistical Analysis
Data are expressed as the mean 6 standard deviation (SD). The comparison of values for multiple treatment groups was performed by one-or two-way analysis of variance (ANOVA) followed by Bonferroni multiple comparison test at P,0.05. Differences between two groups were analyzed using unpaired Student's ttest. A P value of ,0.05 was considered statistically significant.
Results
Synthesis of FACDs and FACD-Ada-Dox and Their Structural Determination by Spectral Techniques
The synthetic procedure for FR targeting b-CD based adamantane-Dox supramolecule is depicted in Figure 2 . To construct the supremolecule, the targeting drug carriers were prepared firstly. Mono-6-amino-6-deoxy-CD (NH 2 -CD) was synthesized as the starting material according to the method of Petter et al. [25] with some modifications. Mono-[6-O-(ptolylsulfonyl)]-b-CD (Ts-CD) was prepared by the reaction of b-CD with p-toluenesulfonyl, and then Ts-CD was transferred to 6-azido-6-amino-b-CD (N 3 -CD) through nucleophilic reaction. Finally, 6-deoxy-6-amino-b-CD (NH 2 -CD) was obtained by a reaction of N 3 -CD and ammioum hydroxide. The resultant watersoluble FACD isomers (a,c and double CD substituted folic acid) were prepared by the coupling of NHS activated NH 2 -CD and folic acid using DCC, the FACDs were purified through ion exchange column, dialysis method, and preparative thin layer chromatography and recrystallization. In addition, the guest molecule Ada-Dox was synthesized according to the reaction of Figure 2b in which Dox was grafted to the adamantine through amide bonding.
The resultant water-soluble FACD isomers were prepared and isolated in a multi-step reaction and the structure of each isomer was characterized by 1D/2D NMR including gradient-selected correlation spectroscopy (g-COSY), heteronuclear multiple-bond correlation spectroscopy (HMBC), and heteronuclear multiplequantum correlation spectroscopy (HMQC), UV spectroscopy, FTIR, HR-MALDI-TOF-MS, and HPLC. The structure of a and c isomers exhibited the stereochemistry as indicated in Figure 2c . The activation energy of diastereomer c-FACD (E Ac = 2729.26 kJ/mol, as modeled by Spartan 08 1. 2. 0) was slightly lower than that of a-FACD (E Aa = 2,736.52 kJ/mol). Lengthening the reaction time up to over 48 hr at 40uC favored the formation of a-FACD, which is taken as the thermodynamic product. In contrast, shortening the reaction time to 8 hr at room temperature (about 20uC) resulted in c-FACD as the dominant product under kinetic control.
The HR-MALDI-TOF-MS spectra of the c-FACD and a-FACD diastereomers as well as FA-conjugated b-CD dimer (FAdiCD) showed the strong molecular ion peaks of C 61 H 88 N 8 NaO 39 at m/z 1,579.414 (intensity 100%), C 61 H 89 N 8 NaO 39 at m/z 1,580.255 (intensity 100%), and C 103 H 158 N 9 NaO 72 at m/z 2,695.992 (intensity 100%), respectively ( Figure 3 and Figures S10, S11 & S12). The enhanced polarity was observed in an order of a-FACD, c-FACD, and FA-diCD with R f values of 0.53, 0.30, and 0.23, respectively, when developed in 1-propanol/ethyl acetate/water/ammonium hydroxide (3:1:2:1, v/v). The preferential product, c-FACD, might result because of its longer linkage and less steric stress than a-substituted, and because the former had a slightly higher energy than the later isomer.
The spectral data of FACDs a were obtained: 1 The structure of the isomers was further identified based on the J-couplings of the protons, and the g-COSY NMR spectra of cand a-FACD in D 2 O exhibited two pairs (solid circles in Figure 2 Additionally, the FTIR spectrum ( Figure S13 ) displayed a number of characteristic absorption bands occurring at 1,650, 1,605, 1,390, 1,260, 1,006, and 802 cm 21 in both the functional and fingerprint regions in which the band at 1,650 cm 21 belongs to the C --O bond stretching vibration of the -CONH 2 group. The band at 1,605 cm 21 related to the bending mode of NH-vibration; 1,383 cm 21 were assigned to the CH 3 symmetrical deformation mode; and the peak at ,800 cm 21 corresponded to the wagging of the saccharide structure of b-CD. These observations provided further evidence for successful FA conjugation with b-CD.
The coupled HPLC/DAD-ELSD in gradient-elution mode was applied to simultaneous quantification of the resulting FA conjugates and drug complexes (Figure 3c and Figure S14) . b-CD, NH 2 -CD and c-FACD were characterized with t R values of 3.0, 3.1, and 3.8 min, respectively.
We conducted circular dichroism analyses for the binding ability, and tested native b-CD at 1.0 mM and at its saturated concentration in DMF (,40 mg/ml), Ada-Dox, FACD, and FACD-Ada-Dox at 1.0 mM in DMF with the cutoff of ,265 nm. The final spectra were the average of three scans obtained after subtracting the spectra of the blank DMF. CD and FA-modified CD displayed ignorable signals, and no obvious spectral change was observed before adding the guest molecule. However, we observed a significant intensity decrease for FACD-Ada-Dox drug complex from 265 to 450 nm in comparison with Ada-Dox prodrug for both positive and negative Cotton effect. Specifically, there were negative and positive extrema at 290 and 350 nm at which molar ellipticity changed by the value of 9.314 and 5.228 deg?cm 2 /dmol, respectively. The association constant, K a , was calculated as 1,639 M 21 by Scatchard plotting method using Prism 5 (GraphPad Software Inc., La Jolla, CA).
Particle Size of FACD-Ada-Dox
FACD-Ada-Dox were evaluated by transmission electron microscopy (TEM) (Figure 5a ) and atomic force microscopy (AFM) (Figure 5b) . The average FACD-Ada-Dox size of the supramolecule was 1.5,2.5 nm and the particles were well dispersed as observed from the TEM and AFM images.
In vitro Release Profiles of the Drug Complexes
The release profiles of Ada-Dox from Ada-Dox and FACDAda-Dox are shown in Figure 6a & b. The amount of released Ada-Dox was quantified using a validated fluorescence method. When Ada-Dox was loaded, Ada-Dox was rapidly released by 27.6% in 30 min and 56.9% in 150 min, with much slower release thereafter and up to 89.6% in 110 hr. The release of Ada-Dox from FACD-Ada-Dox was 2.0-2.8 fold slower than that when Ada-Dox was loaded (P,0.01 or 0.001). After 30 min of incubation, 11.8% of Ada-Dox was released and only 25.8% of Ada-Dox was released from FACD-Ada-Dox after 150 min of incubation. After 150 min, Ada-Dox was continuously and slowly released up to 110 hr. The released drug was 33.8%, 40.5%, and 60.2% after FACD-Ada-Dox was incubated for 10, 60, and 110 hr, respectively.
We also calculated the kinetic parameters when the drug release was calculated up to 4 hr using the one-phase exponential decay model ( Figure 6 
Expression of FR Protein in Different Cells
The folate receptor expression in JAR, HT-29, MCF-7 and 3T3 was determined by Western blot assay ( Figure 7) . The FR expression levels in the cell lines tested were significantly different. JAR cells expressed the highest level of FR, while HT-29 and MCF-7 cells had negligible expression of FR (P,0.001 vs JAR cells).
Cytotoxicity of the Drug Complexes in FR(+) JAR and FR(2) HT-29 and 3T3 cells
To examine how the conjugation of Dox with Ada, FACD and other molecule affected its cytotoxicity, we compared the proliferation of human FR(+) JAR and FR(2) human colon cancer HT-29 cells as well as fibroblast 3T3 cells treated with the drug complexes using the MTT assay. The MTT results are summarized in Table 1 and display in Figure 8 .
Among all drugs tested, the free Dox showed the lowest IC 50 value in all cells when incubated for 24 hr. The conjugation of Dox with FA greatly improved its cytotoxicity in comparison with the prodrug Ada-Dox and non-targeting drug complex, NFACDAda-Dox, specifically to FR(+) JAR cells. It led to 2.26 and 12.36 fold decreases in the IC 50 values to Ada-Dox and NFACD-AdaDox, respectively, and that would be significant in a clinical context. Meanwhile, FA, CD, adamantane, and the carrier FACD barely showed cytotoxicity to all these cells tested. The ability of FACD-Ada-Dox to kill FR(+) cancer cell-compared to NFACDAda-Dox indicates that FA-targeted cyclodextrin complexes deliver their Dox prodrug cargos selectively to cancer cells overexpressing FR. Uptake of the Drug by HT-29, MCF-7, and JAR cells
The Dox-induced fluorescence intensity in HT-29, MCF-7, and JAR cells treated with Dox, Ada-Dox, FACD-Ada-Dox or NFACD-Ada-Dox was quantitatively determined by flow cytometry with the DAPI-stained cell count for normalization. Figure 9 illustrates the Dox-related fluorescence intensity when treated with different drugs by flow cytometry. Table 2 shows the ratio of Dox-related fluorescence intensity in HT-29, MCF-7 and JAR cells treated with different drugs. The data from flow cytometric analysis indicated remarkable differences in Dox-related fluorescence intensity when treated with different drugs in HT-29, MCF-7 and JAR cells ( Figure 10) . In HT-29 cells, treatment with FACD-Ada-Dox significantly resulted in higher Dox-related fluorescence intensity than Dox, Ada-Dox or NFACD-Ada-Dox, with a ratio of 1.70, 1.85 and 2.09, respectively (P,0.001). In MCF-7 cells, FACD-Ada-Dox also showed the highest Doxrelated fluorescence intensity among all four drugs tested, with a ratio of 1.63, 1.87, and 1.98 over Dox, Ada-Dox and NFACDAda-Dox, respectively. In JAR cells overexpressing FR, both FACD-Ada-Dox and Ada-Dox produced significantly higher Doxrelated fluorescence intensity compared to Dox and NFACD-AdaDox. The ratio of Dox-related fluorescence intensity in JAR cells treated with FACD-Ada-Dox over NFACD-Ada-Dox was 7.31. These results suggest that FR-targeted FACD-Ada-Dox enhanced cellular uptake of the drug, probably through FR-mediated endocytosis.
The data from the competition assay in JAR cells (FR positive) are shown in Figure 11 . Our flow cytometric analysis showed that folic acid at 5, 10 or 50 mM significantly inhibited FACD-Ada-DOX uptake in JAR cells (P,0.01 or 0.001), with an FA concentration of 5 mM causing a maximum inhibition of drug uptake. Increasing the FA concentration to 10 or 50 mM caused a lower inhibitory effect on drug uptake, but there was no statistical significance. These data suggests that FACD-Ada-DOX is internalized through FR-mediated mechanism.
Uptake and Subcellular Distribution of the Drug in FR(+) JAR and JEG-3 Cells
The endocytotic uptake of FACD-Ada-Dox by FR(+) JAR cells is demonstrated in Figure 12 . The JAR cells were cultured in drug-containing medium (5.0 mM) for 2 hr followed by paraformaldehyde fixation and staining with DAPI (in blue). Specific patterns of drug accumulation were observed for Dox and AdaDox (in red). The prodrug Ada-Dox demonstrated both cytoplasmic and nuclear localization and this differs from the predominant accumulation of free Dox in the nuclei. Dox was observed to be inside the cell after 30 min of incubation at 37uC. Obviously, fluorescence intensity indicates targeting drug internalize much more drug than non-targeting drug. Binding Modes of FA and Its Conjugates to HHIP The 2WFT structure of HHIP was used in our docking studies. FA could readily be docked into the possible binding site of HHIP containing a human FAa domain, with a CDOCKER interaction energy of 244.53 kcal/mol (Figure 13) . At least three H-bonds were formed with Pro291, Asp398, and Arg410 each. Arg410 also formed charge interaction with FA. When FA was conjugated with a b-CD molecule, the conjugate FACD could be docked into the possible binding site of FRa, with a CDOCKER interaction energy of 295.98 kcal/mol. The binding involved the formation of at least 11 H-bonds and 2 p-p stacks between FA with Arg394. FACD formed H-bonds between Ser411 and the FA moiety, and between Asn292, Pro291, Lys295, or Asp398 and the b-CD moiety ( Figure 13) . Interestingly, Ada-Dox was able to be docked into the possible binding site of HHIP containing a human FAa domain, with an H-bond resulting from the Dox moiety and Lys295 ( Figure 13 ).
ROS Accumulation, GPx activity and GSH Content in H9C2(2-1) Cardiomyocytes and 3T3 Fibroblasts Treated with the Drug Complexes
In mouse H9C2(2-1) cells, treatment with Dox at 2.0 mM for 18 hr only slightly increased the production of ROS by 8.8% (P.0.05), but significantly decreased the GPx activity by 69.0% and the content of intracellular GSH by 92.0% (P,0.001, Figure 14 & Table 3 ). It appeared that Dox might mainly induce the production of other radical species rather than ROS, which considerably consumed intracellular GSH and suppressed GPx activity.
Treatment of H9C2(2-1) cells with Ada-Dox, FACD-Ada-Dox or NFACD-Ada-Dox significantly reduced ROS accumulation compared to cells treated with free Dox or 0.05% DMSO (P,0.001) (Figure 14a) . The GPx activity was increased 337.1% (P,0.001), 80.0% (P.0.05) and 177.2% (P,0.01) in H9C2(2-1) cells treated with Ada-Dox, FACD-Ada-Dox, or NFACD-AdaDox, respectively, compared to cells treated with free Dox. When compared to cells treated with the control vehicle 0.05% DMSO, treatment of H9C2(2-1) cells with Ada-Dox increased GPx activity by 35.4% (P.0.05), while the GPX activity was significantly decreased by 44.4% in cells treated with FACD-Ada-Dox (P,0.05). NFACD-Ada-Dox only slightly reduced the GPx activity compared to the control cells (14.1%, P.0.05). Consistently, treatment of H9C2(2-1) cells with Ada-Dox, FACD-AdaDox or NFACD-Ada-Dox increased intracellular GSH levels 19.1, 11.7 and 12.0 folds, respectively, compared to cells treated with free Dox (P,0.001), respectively, compared to cells treated with free Dox (Figure 14c) . Compared to cells treated with 0.05% DMSO only, treatment of H9C2(2-1) cells with Ada-Dox, FACDAda-Dox or NFACD-Ada-Dox increased intracellular GSH levels 153.4%, 60.8% and 64.2%, respectively (P,0.01 or 0.001). These findings indicate that conjugating of Ada to Dox or FACD to AdaDox reduced the ROS-inducing ability of Dox. Compared to the non-targeted NFACD-Ada-Dox, FACD-Ada-Dox protected mouse cardiomyocytes to a lesser extent in terms of GPx and GSH recovery. This can be explained by increased cytotoxicity due to low expression of FRs in cardiomyocytes exposed to FACDAda-Dox.
In mouse 3T3 fibroblast cells, treatment with Dox at 5.0 mM over 60 min significantly induced the production of ROS (Figure 15 ). The ROS level was decreased by 19.5% and 17.5% when treated with Ada-Dox or FACD-Ada-Dox, respectively (P,0.05, Figure 15 & Table 3 ), compared to cells treated with free Dox. Dox treatment significantly decreased GPx activity and GSH content. The GPx activity and GSH content in 3T3 cells treated with FACD-Ada-Dox increased by 26.4% and 43.4%, respectively, compared to control cells treated with free Dox. The prodrug Ada-Dox reduced the ROS production in 3T3 cells by 19.5%, but did not alter the GPx activity and GSH content, compared to cells treated with free Dox. Compared to the treatment with Dox or Ada-Dox, both FACD-Ada-Dox and NFACD-Ada-Dox significantly increased the GPx activity and GSH content (P,0.05) in 3T3 cells. Since 3T3 cells lack FR expression, the recovering ability of FACD-Ada-Dox and NFACD-Ada-Dox for GPx and GSH is comparable.
Discussion
A variety of receptors have been identified as markers for carcinomas. FA is a hydrophilic B-complex vitamin which plays an essential role in mammalian cell survival by participating in the biosynthesis of purines, thymidylate, and certain amino acids [26] . Leucovorin (5-formyl-tetrahydrofolate) and reduced folates (e.g. 5-methyl-tetrahydrofolate) are precursors of one-carbon donors in the de novo biosynthesis of purines and thymidylate. FA and its derivatives can cross cells by three mechanisms: a) the reduced folate carrier (RFC/SLC19A1), a bidirectional anion exchanger that has a high affinity for reduced folate co-factors and antifolates (e.g. methotrexate), but a low affinity for FA; RFC can take up folate cofactors and export various organic anions, including thiamine pyrophosphate; b) the folate receptor-a (FRa/FR/ Figure 10 . The Dox-related fluorescence intensity in HT-29, MCF-7 and JAR cells treated with Dox, Ada-Dox, FACD-Ada-Dox or NFACD-Ada-Dox. The drug at 5.0 mM was added into the 35-mm petri dishes containing 2610 5 cells in 3.0 ml culture medium. The cells were incubated for 2 hr to allow uptake of the drugs. The harvested cells were stained with 20 ml DAPI at 1.0 mM for flow cytometric analysis. Cells incubated with DMEM alone were used as the control. ** P,0.01; *** P,0.001. doi:10.1371/journal.pone.0062289.g010 Table 2 . FLOR1 ) that is an energy-dependent, high-affinity, low-capacity folate-binding protein anchored in the plasma membrane through a glycosylphosphatidylinositol moiety and translocate folates unidirectionally into cells via an endocytotic process; and c) a ubiquitously expressed proton-coupled folate transporter (PCFT/ SLC46A1) [27] . Unlike FRa/FLOR1, both RFC and PCFT are membrane-spanning receptors that facilitate bidirectional transport of reduced folate across the plasma and endosomal membranes. Members of the FR family include FRa/FLOR1, FRb/FLOR2, FRc/FLOR3, and FRd/FLOR4, which can bind FA and reduced folates, and transport them into cells. FRa/ FLOR1 and FRb/FLOR2 are both GPI-anchored proteins with two N-glycosylation sites, with a high affinity for FA (K d = ,1 nM). In normal tissue, FRa/FLOR1 is mainly expressed on the apical surface of a subset of polarized epithelial cells whereas its aberrant expression has been prominently correlated with malignancies of epithelial origin. FR/FRa/FOLR1 is highly over-expressed (40-90%) on primary and metastatic human cancers of the ovary, lung, breast, colon, endometrium, kidney, and brain, but has only limited distribution in healthy tissues [28] [29] [30] . This exclusivity has led to the exploitation of FA as an important ligand for specific targeting by diagnostic or therapeutic agents. Even after conjugation to nano-drug complexes, FA acts as a high-affinity ligand (K a .10 210 M), enhancing tumor uptake with little involvement of non-tumor tissue compared to conventional chemotherapy. FA derivatization allows the selective delivery of cytotoxic or diagnostic agents to pathologic tissue in the presence of normal cells, and FR can readily and actively internalize bound FA and FA-conjugated compounds via receptor-mediated endocytosis [28, 29] . It is hypothesized that FA conjugation to anticancer drugs will improve drug selectivity, thereby avoiding the collateral damage that accompanies their uptake by healthy cells.
For the first time, we have successfully synthesized and purified novel water-soluble, FA-conjugated b-CD-based targeting drug proton resonance at 2.0 to 5.0 ppm were assigned to the protons in the CD framework for a/c substituted isomers as well as FAdiCD.
Cyclodextrins are cyclic oligomers of a-D-glucose bonded through a-(1, 4) linkages formed during bacterial digestion of cellulose. The shape of a CD molecule is similar to a truncated cone with a hydrophilic outer surface and a lipophilic central cavity. CDs are widely used as functional macro cyclic host molecules in supramolecular chemistry due to their low cost, water solubility, and biocompatible properties, along with their substantial ability to entrap drug molecules within their internal cavity [31, 32] . b-CD has the capability to encapsulate up to seven water molecules, and the main driving force of complex formation is the release of enthalpy-rich water molecules from the cavity. Water molecules are displaced by more hydrophobic guest molecules present in the solution to attain an apolar association and decrease of CD ring strain, which results in a lower, more stable energy state in which substitution affects the electron density and the conjugation system. The binding of guest molecules within the host CD is not fixed or permanent but rather is in dynamic equilibrium. The signal from the protons of water is suppressed in our experiment and we found that the CD bucket in the FACDs could entrap the solvent mixture (1-propanol/ethyl acetate/ water/ammonium hydroxide) as well as trace amount of free folate to form oily, light yellow complex with similar polarity. While it competed with other solvents when dissolved, the complexation could interfere with the NMR spectrum to some extent. This by-product could be removed through repeated recrystallization.
The formation of guest-host inclusion complexes between AdaDox and CDs has proven to be an excellent model system for studying the nature of noncovalent bonding forces in aqueous solution [33] . The interaction of Ada-Dox with CDs resulted in b-CD with an inner-cavity diameter of ,7.0 Å . The adamantyl group of Ada-Dox also had a diameter of ,7 Å , and it has been confirmed that the strongest binding occurred between adamantine and b-CD, consistent with the near-perfect match between the cavity and guest diameter. The CD spectra also support the hostguest interaction between FACD and the adamantine group of Ada-Dox (Figure 4) . Our findings indicates that Ada-Dox interacts with FACD and results in conformational changes at the CD cavity binding site followed by chiral microenvironment changes for the whole drug complex supramolecule.
Besides targeting function, the FACD-Ada-Dox complex is intended to control the release of drug. Folic acid-attached CDs preserve the ability to form non-covalent complexes with the guest drug and in so doing altering their physicochemical properties. The retarded and sustained drug release profile was observed for FACD-Ada-Dox. At the same drug load, the cumulative release of the prodrug in water after 1.5 hr approached 50% compared to ,20% in the prodrug, which is desired to improve efficacy and minimize toxicity. Table 3 . Effects of the drug complexes on ROS levels, GPx activity and intracellular GSH cofntents in mouse H9C2(2-1) cardiomyocytes and 3T3 fibroblast cells. The targeted drug FACD-Ada-Dox exhibits significantly enhanced cellular uptake compared with the non-targeted drugs by FR(+) JAR cells. The tumor targeting of FACD-Ada-Dox facilitates faster and increased cellular internalization than NFACD-Ada-Dox. The ligand binding strategy allows preferential internalization of FACD-Ada-Dox into FR(+) cancer cells. FACDAda-Dox is taken up at a rate of eight times faster than NFACDAda-Dox, while for the HT-29 and MCF-7 cells on which FR is poorly expressed, the binding affinity is comparable among Dox, Ada-Dox, FACD-Ada-Dox, and NFACD-Ada-Dox, except that targeting results in slightly higher drug uptake than non-targeted drugs. The uptake of the targeted drug molecule in JAR cells was significantly inhibited by folate at 5-50 mM. This offers further evidence that the targeted nanoparticles are internalized through FR-mediated pathway. Consistently, the cell killing effects of FACD-Ada-Dox are significantly higher than NFACD-Ada-Dox in FR(+) cells.
It is expected that alleviating cardiotoxicity and enhancing the anticancer efficacy will be achieved when Dox is administered in a slow-release targeting drug complex allowing specific accumulation in tumor cells and reducing the free radicals thought to cause cardiotoxicity. The classical strategies to improve the efficacy and reduce organ toxicity of Dox include: a) enhancing Dox uptake by tumor cells via proper targeting approach and nanotechnology; b) Dox-based prodrugs that can readily activated within tumor cells via liposomal encapsulation or conjugation with antibodies, peptides, or synthetic polymers; c) diminishing Dox deactivation; d) reducing Dox efflux from tumor cells that is often mediated by active drug transporters such as MDR1; e) blocking the antioxidant defense of tumor cells; and f) modulating signaling pathways and cell cycles to sensitize tumor cells to Dox therapy [34] . Each of these means has certain advantages and limitations and sometimes a combination of these strategies may be required to maximize tumor cell killing and minimize organ toxicity [35] .
The clinical usage of Dox is limited by cumulative, dose-related, progressive myocardial damage that may lead to congestive heart failure in cancer patients [15] . The cardiotoxicity induced by Dox appears to be a multi-factorial process caused primarily by oxidative stress-induced free radicals involving both Dox and its toxic metabolites such as doxorubicinol [13, 15] . The mechanism for the therapeutic effect of Dox is thought to be different from that of its cardiotoxicity. The slow-releasing targeted drug complex is expected to elicit less deleterious effects on normal cells. The results showed that ROS accumulation inside cells after FACDAda-Dox and Ada-Dox treatment was less than for free Dox in both mouse H9C2(2-1) cardiomyocytes and fibroblast 3T3 cells. Furthermore, the activity of GPx and GSH content were significantly increased in H9C2(2-1) cells treated with FACDAda-Dox compared to cells treated with free Dox. This suggests that the higher GSH levels seen with FACD-Ada-Dox could be sufficient to remarkably decrease ROS levels, thereby maintaining the function and increasing survival for normal cardiomyocytes under chemotherapy.
The protective effect of FACD-Ada-Dox is more apparent than the prodrug Ada-Dox in both H9C2(2-1) cardiomyocytes and fibroblast 3T3 cells. This suggests that targeting FR in FR(+) cardiomyocytes is not the main determinant for Dox-induced cardiotoxicity. A lower ROS production and higher increase in GPx activity and GSH content in cells treated with FACD-AdaDox than Ada-Dox can be ascribed to a lesser release of free Dox from the FR-targeted complex than the prodrug Ada-Dox, resulting in less uptake of cardiotoxic Dox. A more significant protection of FACD-Ada-Dox and Ada-Dox in H9C2(2-1) cardiomyocytes than fibroblasts is likely due to differential expression of FR protein and binding affinity to FRs. In addition, the distinct expression and activity levels of RFC and PCFT in different types of cells that participate in FA transport across the membrane may also contribute to the differential protection observed in this study. Drug treatment time is another important factor that can affect the Dox-induced ROS production and the protective effect of FACD-Ada-Dox and Ada-Dox. A longer drug exposure may facilitate the conversion of Dox to its cardiotoxic metabolites such as 7-deoxy-doxorubicinone and doxorubicinol, thereby enhancing the signaling transduction for the production of ROS and reactive nitrogen species.
In this study, we synthesized the Ada-Dox conjugate rather than Dox as the cargos. Adamantine has very strong host-guest interaction by molecular recognization and high binding affinity with the cyclodextrin cavity since the geometry of the adamantine fits well with the inner cavity, and in this way the drug will be entrapped tightly by CD molecules and thus reducing drug release. Another reason is that Ada-Dox preserve strong fluorescence and we could readily trace the drug inside cells.
Based on the data from our MTT, cellular uptake and binding and cardiomyocyte protection assays, the prodrug Ada-Dox has showed totally different behaviors compared to free Dox. It is less toxic to the cancer cells than Dox in vitro and can protect the cardiomyocytes from Dox-induced injuries. These findings suggest that design of prodrugs for Dox represents an alternative way to ameliorate the organ toxicity and enhance the anticancer efficacy of Dox. A number of Dox-based prodrugs have been synthesized and reported [36] [37] [38] , but their efficacy and safety profiles must be validated in cancer patients.
Since the crystal structure of human FR members is not resolved so far, we used the structure of HHIP containing a FRa domain to examine whether conjugation of b-CD could affect the FA-FR binding. The results showed that both FA and FACD could be readily docked into the possible binding site of HHIP and Ada-Dox could form weak binding with HHIP. Because FACDAda-Dox is a supramolecule with nonconvalent binding, we have difficulties in generating this larger molecule and docking into HHIP using the CDOCKER module in Discovery Studio 3.1. Our docking results suggest that FA, FACD and FACD-Ada-Dox could bind the FRs on the surface of cancer cells and thus facilitate endocytosis.
In summary, we have reported the successful synthesis and purification of novel water soluble, folic acid-conjugated bcyclodextrin-based targeting drug supramolecules with adamantine-doxorubicin as the therapeutic cargo. The structures have been rigorously characterized by HR-MALDI-TOF-MS, 1D/2D NMR, FTIR, HPLC, and circular dichroism. The targeted drug complex possesses high drug association and sustained drug release properties with good biocompatibility and physiological stability. Cellular uptake and FR binding competitive experiments demonstrated an efficient and preferentially targeted delivery of Dox into FR-positive carcinomatous cells. Moreover, the decrease in ROS levels and increase in GPx activity and GSH content in cardiomyocytes exposed to the targeted Dox complex indicate the cardiotoxicity by doxorubicin could be ameliorated by the selective targeting of FR. The novel folic acid-conjugated b-CD based drug complex reported here might be promising as an anti-tumor treatment. In vivo animal studies are undertaking at our laboratory. 
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